Role of adenosine triphosphate-sensitive potassium channel inhibition in shock states: Physiology and clinical implications

Shock

Volumn 28, Issue 4, 2007, Pages 394-400

  Lange, Matthias ^a,c   Morelli, Andrea ^b   Ertmer, Christian ^a   Bröking, Katrin ^a   Rehberg, Sebastian ^a   Aken, Hugo Van ^a   Traber, Daniel L ^c   Westphal, Martin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Adenosine triphosphate sensitive potassium channel inhibition; Hemorrhage; Sepsis; Sulfonylureas; Vasodilatory shock

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; LACTIC ACID; POTASSIUM CHANNEL BLOCKING AGENT; SULFONYLUREA; TOLAZAMIDE; VOLTAGE GATED CALCIUM CHANNEL;

ANAEROBIC METABOLISM; ARTERIAL PRESSURE; ARTERY MUSCLE; BLOOD FLOW; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CALCIUM TRANSPORT; CLINICAL TRIAL; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HEART OUTPUT; HEART RATE; HEMODYNAMIC PARAMETERS; HEMODYNAMICS; HEMORRHAGIC SHOCK; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MEMBRANE DEPOLARIZATION; MUSCLE TONE; NONHUMAN; OXYGEN SUPPLY; PATHOPHYSIOLOGY; PH; PROTEIN FUNCTION; REVIEW; SEPTIC SHOCK; SHOCK; SYSTEMIC VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

ADENOSINE TRIPHOSPHATE; ANIMALS; HEMORRHAGE; HUMANS; MODELS, BIOLOGICAL; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; SHOCK; SHOCK, SEPTIC;

EID: 34548676568     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/shk.0b013e318050c836     Document Type: Review

References (58)

1. Ince C, Sinaasappel M: Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 27:1369-1377, 1999.
2. Jarrar D, Chaudry IH, Wang P: Organ dysfunction following hemorrhage and sepsis: mechanisms and therapeutic approaches [Review]. Int J Mol Med 4:575-583, 1999.
3. Szabo C, Salzman AL: Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock 5:391-394, 1996.
4. + channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 89:2071-2074, 1992.
5. Kloner RA, Speakman MT, Przyklenk K: Ischemic preconditioning: a plea for rationally targeted clinical trials. Cardiovasc Res 55:526-533, 2002.
6. Zhao ZQ, Vinten-Johansen J: Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 70:200-211, 2006.
7. Nelson MT, Quayle JM: Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268(4 Pt 1):C799-C822, 1995.
8. + channels in cardiac muscle. Nature 305:147-148, 1983.
9. Ashcroft SJ, Ashcroft FM: Properties and functions of ATP-sensitive K-channels. Cell Signal 2:197-214, 1990.
10. + channels in skeletal muscle by intracellular protons. Nature 343:375-377, 1990.
11. + channels by hypoxia in smooth muscle cells isolated from the pig coronary artery. J Physiol 483:29-39, 1995.
12. Keung EC, Li Q: Lactate activates ATP-sensitive potassium channels in guinea pig ventricular myocytes. J Clin Invest 88:1772-1777, 1991.
13. Nelson MT, Patlak JB, Worley JF, Standen NB: Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 259:C3-C18, 1990.
14. Daut J, Maier-Rudolph W, Von Beckerath N, Mehrke G, Gunther K, Goedel-Meinen L: Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 247:1341-1344, 1990.
15. Quayle JM, Nelson MT, Standen NB: ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77:1165-1232, 1997.
16. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 345:588-595, 2001.
17. Yan FF, Casey J, Shyng SL: Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex. J Biol Chem 281:33403-33413, 2006.
18. + channels in smooth muscle. J Physiol 572:617-624, 2006.
19. +-channel opener sensitivity of KATP channels: functional coupling of Kir6.2 and SUR1 subunits. J Gen Physiol 114:203-213, 1999.
20. Vanelli G, Hussain SN, Aguggini G: Glibenclamide, a blocker of ATP-sensitive potassium channels, reverses endotoxin-induced hypotension in pig. Exp Physiol 80:167-170, 1995.
21. Evgenov OV, Pacher P, Williams W, Evgenov NV, Mabley JG, Cicila J, Siko ZB, Salzman AL, Szabo C: Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats. Crit Care Med 31:2429-2436, 2003.
22. ATP-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 272:H688-H694, 1997.
23. Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I: The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 29:71464-71471, 2003.
24. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B: Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 168:165-172, 2003.
25. Taylor BS, Geller DA: Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock 13:413-424, 2000.
26. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122-1125, 1997.
27. Thiemermann C: Nitric oxide and septic shock. Gen Pharmacol 29:159-166, 1997.
28. Titheradge MA: Nitric oxide in septic shock. Biochim Biophys Acta 1411:437-455, 1999.
29. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, et al.: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32:21-30, 2004.
30. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR: Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313-2319, 2003.
31. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA: The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416-1421, 2001.
32. Westphal M, Stubbe H, Sielenkamper AW, Ball C, Van Aken H, Borgulya R, Bone HG: Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit Care Med 31:1502-1508, 2003.
33. Albanese J, Leone M, Delmas A, Martin C: Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 33:1897-1902, 2005.
34. Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, Vernaglione E, Pelaia P, Pietropaoli P: Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 30:597-604, 2004.
35. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. Lancet 359:1209-1210, 2002.
36. Westphal M, Stubbe H, Sielenkamper AW, Borgulya R, Van Aken H, Ball C, Bone HG: Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 29:301-308, 2003.
37. Ioannou G, Doust J, Rockey DC: Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev CD002147, 2001.
38. Westphal M, Freise H, Kehrel BE, Bone HG, Van Aken H, Sielenkamper AW: Arginine vasopressin compromises gut mucosal microcirculation in septic rats. Crit Care Med 32:194-200, 2004.
39. Gardiner SM, Kemp PA, March JE, Bennett T: Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre- or post-treatment with glibenclamide. Br J Pharmacol 128:1772-1778, 1999.
40. Lange M, Szabo C, Van Aken H, Williams W, Traber DL, Daudel F, Broking K, Salzman AL, Bone HG, Westphal M: Short-term effects of glipizide (an adenosine triphosphate-sensitive potassium channel inhibitor) on cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep. Shock 26:516-521, 2006.
41. Jackson WF: Arteriolar tone is determined by activity of ATP-sensitive potassium channels. Am J Physiol 265:H1797-H1803, 1993.
42. Lange M, Williams W, Bone HG, Van Aken H, Broeking K, Morelli A, Hucklenbruch C, Daudel F, Ertmer C, Stubbe H, et al.: Continuously infused glipizide reverses the hyperdynamic circulation in ovine endotoxemia. Shock 27:701-706, 2007.
43. Warrillow S, Egi M, Bellomo R: Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 34:980-985, 2006.
44. Preiser JC, Zhang H, Debelle F, Fesler P, Kafi SA, Naeije R, Vincent JL: Hemodynamic effects of glibenclamide during endotoxemia: contrasting findings in vitro versus in vivo. Shock 19:223-228, 2003.
45. Oliver JA, Landry DW: Potassium channels and septic shock. Crit Care Med 34:1255-1257, 2006.
46. Morelli A, Lange M, Ertmer C, Bröking K, Van Aken H, Orecchioni A, Rocco M, Bachetoni A, Traber DL, Landoni G, et al.: Glibenclamide dose response in patients with septic shock: effects on norepinephrine requirements, cardiopulmonary performance and global oxygen transport Shock. In press.
47. Kauvar DS, Wade CE: The epidemiology and modern management of traumatic hemorrhage: US and international perspectives. Crit Care 9(Suppl 5):1-9, 2005.
48. Maybauer DM, Salsbury JR, Westphal M, Maybauer MO, Salzman AL, Szabo C, Westphal-Varghese BB, Traber LD, Traber DL: The ATP-sensitive potassium-channel inhibitor glibenclamide improves outcome in an ovine model of hemorrhagic shock. Shock 22:387-391, 2004.
49. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359-1367, 2001.
50. Yellon DM, Downey JM: Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83:1113-1151, 2003.
51. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV: Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44:1103-1110, 2004.
52. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119-124, 1999.
53. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA: Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174:169-174, 2006.
54. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998. No authors listed.
55. + channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev 22:341-347, 2006.
56. Domoki F, Perciaccante JV, Veltkamp R, Bari F, Busija DW: Mitochondrial potassium channel opener diazoxide preserves neuronal-vascular function after cerebral ischemia in newborn pigs. Stroke 30:2713-2718, 1999; discussion 2718-2719.
57. Busija DW, Katakam P, Rajapakse NC, Kis B, Grover G, Domoki F, Bari F: Effects of ATP-sensitive potassium channel activators diazoxide and BMS-191095 on membrane potential and reactive oxygen species production in isolated piglet mitochondria. Brain Res Bull 66:85-90, 2005.
58. Lehto P, Laine K, Kivisto KT, Neuvonen PJ: The effect of pH on the in-vitro dissolution of three second-generation sulphonylurea preparations: mechanism of antacid-sulphonylurea interaction. J Pharm Pharmacol 48:899-901, 1996.